Short-term effects of blood pressure control and antihypertensive drug regimen on glomerular filtration rate: the African-American Study of Kidney Disease and Hypertension Pilot Study.

[1]  J. Breyer,et al.  Effects of Blood Pressure Control on Progressive Renal Disease in Blacks and Whites , 1997 .

[2]  J. Breyer,et al.  Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators. , 1997, Kidney international.

[3]  R. Toto,et al.  Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. , 1996, Controlled clinical trials.

[4]  P. Whelton,et al.  Recruitment experience in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. , 1996, Controlled clinical trials.

[5]  P. Whelton,et al.  Appointment attendance, pill counts, and achievement of goal blood pressure in the African American Study of Kidney Disease and Hypertension Pilot Study. , 1996, Controlled clinical trials.

[6]  G. Beck,et al.  Short-term effects of protein intake, blood pressure, and antihypertensive therapy on glomerular filtration rate in the modification of diet in renal disease study: Modification of diet in renal disease study group , 1996 .

[7]  E. Ritz.  Are antihypertensive drugs similar in protecting the kidney? , 1995, American journal of hypertension.

[8]  R. Toto,et al.  "Strict" blood pressure control and progression of renal disease in hypertensive nephrosclerosis. , 1995, Kidney international.

[9]  K. Kudo.  Renal function during antihypertensive treatment , 1995, The Lancet.

[10]  T. Louis,et al.  Long-term effects of antihypertensive agents on proteinuria and renal function. , 1995, Archives of internal medicine.

[11]  J. Miller,et al.  Early predictors of 15-year end-stage renal disease in hypertensive patients. , 1995, Hypertension.

[12]  L. Hansson,et al.  ACE inhibition preserves renal function better than beta-blockade in the treatment of essential hypertension. , 1995, Blood pressure.

[13]  A. Mimran,et al.  Angiotensin-converting enzyme inhibitors versus calcium antagonists in the progression of renal diseases. , 1994, American journal of hypertension.

[14]  M. Epstein,et al.  Effects of calcium antagonists on renal hemodynamics and progression of nondiabetic chronic renal disease. , 1994, Archives of internal medicine.

[15]  G. Beck,et al.  The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease , 1994 .

[16]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .

[17]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[18]  B. Morgenstern,et al.  Human blood pressure determination by sphygmomanometry. , 1993, Circulation.

[19]  J. Neaton,et al.  Ethnicity and renal disease: lessons from the Multiple Risk Factor Intervention Trial and the Treatment of Mild Hypertension Study. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  L. Agodoa,et al.  Kidney disease and hypertension in blacks: scope of the problem. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  L. Ruilope,et al.  Calcium antagonists and renal protection , 1993, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[22]  M. Epstein.  Calcium Antagonists and Renal Protection: Current Status and Future Perspectives , 1992 .

[23]  A. Zuccalà,et al.  Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. , 1992, Kidney international.

[24]  R. Toto,et al.  Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. , 1991, Annals of internal medicine.

[25]  Gillum Rf.  Cardiovascular disease in the United States: an epidemiologic overview. , 1991, Cardiovascular clinics.

[26]  E. Saunders.  Cardiovascular diseases in blacks. , 1991, Cardiovascular clinics.

[27]  Bauer Jh,et al.  Renal protection in essential hypertension: how do angiotensin-converting enzyme inhibitors compare with calcium antagonists? , 1990 .

[28]  Eisner Gm.  Hypertension: racial differences. , 1990 .

[29]  S. Rosansky,et al.  The association of blood pressure levels and change in renal function in hypertensive and nonhypertensive subjects. , 1990, Archives of internal medicine.

[30]  G. Beck,et al.  Utility of Radioisotopic Filtration Markers in Chronic Renal Issufficiency: Simultaneous Comparison of 125I-Iothalamate, 169Yb-DTPA, 99mTc-DTPA, and Inulin , 1990 .

[31]  D. de Zeeuw,et al.  Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Current experience and future directions. , 1989, Annals of internal medicine.

[32]  P. Whelton,et al.  Hypertension as a Risk Factor for Renal Disease Review of Clinical and Epidemiological Evidence , 1989, Hypertension.

[33]  H. Dustan,et al.  Renal insufficiency in treated essential hypertension. , 1989, The New England journal of medicine.

[34]  Grim Ce.  Renin and aldosterone in hypertensive blacks. , 1987 .

[35]  J. Ware,et al.  Random-effects models for longitudinal data. , 1982, Biometrics.

[36]  E. B. Pedersen,et al.  Effect of antihypertensive treatment on urinary albumin excretion, glomerular filtration rate, and renal plasma flow in patients with essential hypertension. , 1976, Scandinavian journal of clinical and laboratory investigation.